You just read:

U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

Janssen Biotech, Inc.

Dec 21, 2017, 08:00 ET